Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropaties: a Cross-over Randomized Clinical Trial

• Status: Not yet recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to asses the serum uric-acid lowering effect of losartan in children with proteinuric nephropaties. Patients already treated with enalapril will be randomized to receive losartan or enalapril in a cross-over designed study. Those who recruit the inclusion criteria will receive enalapril and/or losartan during a one month period, followed by a 15 days of wash out (under enalapril treatment). On day 46, the second period of 30 days of treatment starts (enalapril or losartan, whichever was not received initially). Before randomization, a baseline 24 hours urine and a fasting blood sample will be obtained to asses uric acid excretion and serum uric acid values along with renal function and electrolyte levels. Then, similar determinations will be performed at days 30, 46 and 76.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General de Niños Pedro de Elizalde
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Children with poteinuric nephropaties already treated with enalapril under our care.

• Age between 3 and 12 years.

• Normal blood pressure.

Exclusion Criteria:

• Patients with high blood pressure.

• Post menarche female patients.

• Patients with hypouricemia (< 2 mg/dL).

• Patients treated with diuretics.

• Patients with absolute or relative contraindications to receive RAAS antagonists (glomerular filtration < 30 ml/in/1,73 m2, serum potassium > 5,5 mEq/L).

• Patients with active rheumatic diseases.

• Patients treated with dual blockade of the RAAS (enalapril +losartan).

• Patients treated with calcineurin inhibitors.